MedTrace Logo

A Trial of Behavioral Economic Interventions to Reduce Cardiovascular Disease (CVD) Risk

NCT01346189 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1503

Last updated 2017-12-06

Study results available
· View outcomes & findings →

Summary

Using a 4-arm, cluster-randomized controlled trial, the investigators will test the effectiveness of different behavioral economic interventions in increasing statin use and reducing LDL cholesterol among patients with poor cholesterol control who are at very high risk for CVD. The investigators will test these approaches among primary care physicians and their patients at very high risk of CVD at Geisinger Health System and University of Pennsylvania outpatient clinics.

Conditions

Interventions

BEHAVIORAL

Behavioral Economic Intervention

Various combinations of financial incentives to patients and providers.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Geisinger Clinic

    collaborator OTHER

  • Brigham and Women's Hospital

    collaborator OTHER

  • Harvard School of Public Health (HSPH)

    collaborator OTHER

  • Carnegie Mellon University

    collaborator OTHER

  • Harvard Vanguard Medical Associates

    collaborator OTHER

  • University of Pennsylvania

    lead OTHER

Principal Investigators

  • Kevin Volpp, MD, PhD · University of Pennsylvania

  • David Asch, MD, MBA · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01346189 on ClinicalTrials.gov